Lipocine (LPCN) News Today $3.16 -0.13 (-3.95%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPCN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period HC Wainwright Reiterates "Buy" Rating for Lipocine (NASDAQ:LPCN)June 29 at 2:21 AM | americanbankingnews.comLipocine doses first patient in phase 3 trial for oral PPD treatmentJune 28 at 7:00 AM | uk.investing.comLipocine begins dosing in Phase III postpartum depression trial of LPCN 1154June 27 at 6:06 PM | msn.comLipocine (NASDAQ:LPCN) Share Price Crosses Below 200 Day Moving Average - Here's WhyJune 27 at 4:23 AM | americanbankingnews.comLipocine Begins Phase 3 Trial for LPCN 1154June 26, 2025 | tipranks.comLipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum DepressionJune 26, 2025 | finanznachrichten.deLipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum DepressionJune 26, 2025 | prnewswire.comLipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025June 23, 2025 | prnewswire.comLe partenaire de Lipocine dépose une demande d’approbation au Canada pour un médicament TRT oralJune 9, 2025 | fr.investing.comLipocine Announces Filing of New Drug Submission for TLANDO® in CanadaJune 9, 2025 | prnewswire.comLipocine’s LPCN 1148 Gains Fast Track DesignationMay 22, 2025 | tipranks.comLipocine's LPCN 1148 Highlighted in the June 2025 Edition of HepatologyMay 22, 2025 | prnewswire.comLipocine to Present at A.G.P. Healthcare ShowcaseMay 14, 2025 | tipranks.comLipocine to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 14, 2025 | prnewswire.comLipocine Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2025May 8, 2025 | prnewswire.comLipocine inks license and supply agreement for TLANDO in BrazilMay 7, 2025 | msn.comLipocine s’associe à Aché pour commercialiser TLANDO au BrésilMay 7, 2025 | fr.investing.comLipocine Partners with Aché for TLANDO® in BrazilMay 6, 2025 | tipranks.comLipocine Announces License and Supply Agreement for TLANDO® in BrazilMay 6, 2025 | prnewswire.comL’action LPCN atteint son plus bas niveau sur 52 semaines à 2,91$April 7, 2025 | fr.investing.comLipocine Inc. Reports 2024 Financial TurnaroundApril 3, 2025 | tipranks.comLipocine’s Phase III trial of LPCN 1154 to begin for postpartum depressionMarch 27, 2025 | finance.yahoo.comLipocine initiates Phase 3 trial for LPCN 1154March 27, 2025 | markets.businessinsider.comLipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154March 26, 2025 | prnewswire.comLIPOCINE Earnings Results: $LPCN Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comLipocine Says FDA Recommends Removing Cardiovascular Risk Warning From Testosterone Product LabelsMarch 14, 2025 | nasdaq.comLipocine Announces Financial Results for the Full Year Ended December 31, 2024March 13, 2025 | prnewswire.comLipocine Inc.: Lipocine Announces FDA Labeling Changes for Testosterone ProductsMarch 12, 2025 | finanznachrichten.deLipocine Announces FDA Labeling Changes for Testosterone ProductsMarch 12, 2025 | prnewswire.comL’action LPCN atteint son plus bas niveau sur 52 semaines à 2,92$March 5, 2025 | fr.investing.comLPCN stock touches 52-week low at $3.15 amid market challengesFebruary 26, 2025 | investing.comL'action LPCN atteint son plus bas niveau sur 52 semaines à 3,15$February 24, 2025 | fr.investing.comLipocine planifie une étude de phase 3 pour son médicament contre la dépression post-partumFebruary 6, 2025 | fr.investing.comLipocine plans phase 3 study for postpartum depression drugFebruary 6, 2025 | msn.comLipocine Receives Updated Regulatory Guidance on LPCN 1154February 6, 2025 | prnewswire.comLipocine Inc. Common Stock (LPCN) Latest After Hours TradesFebruary 2, 2025 | nasdaq.comLa FDA accélère le traitement de la sarcopénie de LipocineDecember 17, 2024 | fr.investing.comLipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated CirrhosisDecember 17, 2024 | finanznachrichten.deLipocine's LPCN 1148 Gets Fast Track Status To Treat Sarcopenia In Decompensated Cirrhosis PatientsDecember 17, 2024 | markets.businessinsider.comFDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated CirrhosisDecember 17, 2024 | prnewswire.comLipocine announces publication, discussion of LPCN 1148November 18, 2024 | markets.businessinsider.comLipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut SessionNovember 18, 2024 | prnewswire.comLipocine Announces Financial Results for the Third Quarter Ended September 30, 2024November 7, 2024 | prnewswire.comLipocine conclut un accord pour commercialiser TLANDO en Corée du SudOctober 31, 2024 | fr.investing.comLipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South KoreaOctober 31, 2024 | prnewswire.comLipocine annonce des résultats prometteurs pour l'étude sur la brexanolone oraleOctober 12, 2024 | fr.investing.comLipocine Announces Positive Oral Brexanolone Quantitative EEG ResultsOctober 10, 2024 | prnewswire.comLipocine signs supply and distribution agreement with Pharmalink for TlandoOctober 9, 2024 | finance.yahoo.comLipocine Inks Distribution Deal With Pharmalink To Commercialize TLANDO In GCC CountriesOctober 8, 2024 | markets.businessinsider.com Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address LPCN Media Mentions By Week LPCN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPCN News Sentiment▼0.140.90▲Average Medical News Sentiment LPCN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPCN Articles This Week▼91▲LPCN Articles Average Week Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IGMS News INCR News IMUX News ICCC News BMEA News STRO News ADAP News SKYE News IKNA News CLSD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LPCN) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPCN Stock Alerts